Company Filing History:
3 out of 1,343 
1 out of 49 Years Active: 2022-2025
Title: Innovator Spotlight: Janelle Waite from Bronx, NY
Introduction
Janelle Waite, based in the Bronx, NY, is an accomplished inventor who has made significant contributions to the field of immunotherapy through her innovative work on bispecific antibodies. With a total of three patents to her name, Waite is at the forefront of research focused on improving treatments for various types of tumors.
Latest Patents
Waite's latest inventions include two notable patents:
1. **Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof** - This invention encompasses bispecific antigen-binding molecules which include a first domain that specifically binds to human CD28, alongside a second domain that binds to human PSMA. These bispecific molecules show potential in inhibiting the growth of tumors that express PSMA, such as prostate tumors, making them valuable in the treatment of diseases where an enhanced immune response is beneficial.
2. **Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof** - Similarly, this invention features bispecific antigen-binding molecules that target human CD28 and human MUC16. These molecules are capable of inhibiting tumor growth in cancers like ovarian tumors, and they serve a purpose in therapeutic areas that require a targeted immune response.
Career Highlights
Throughout her career, Janelle Waite has worked with leading organizations, including Regeneron Pharmaceuticals, Inc. Her experience in these high-profile companies has allowed her to contribute to groundbreaking research and development in the pharmaceutical field.
Collaborations
Waite has collaborated with esteemed professionals in the industry, notably Andrew J Murphy and Dimitris Skokos. These collaborations reflect her commitment to working alongside talented colleagues to foster innovation and advance therapeutic solutions for various medical challenges.
Conclusion
Janelle Waite’s work exemplifies the spirit of innovation within the immunotherapy landscape. With her patents focusing on bispecific antibodies, she plays a crucial role in the ongoing efforts to enhance cancer treatments and improve patient outcomes through targeted therapeutic strategies.